Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.
Hydrochlorothiazide and lisinopril is a prescription fixed-dose combination for hypertension. Lisinopril is an angiotensin-converting enzyme inhibitor and hydrochlorothiazide is a thiazide diuretic. Current tablet strengths include 10 mg/12.5 mg, 20 mg/12.5 mg, and 20 mg/25 mg.
read more about hydrochlorothiazide and lisinopril ...Lisinopril inhibits angiotensin-converting enzyme and reduces formation of angiotensin II and aldosterone. Hydrochlorothiazide increases urinary sodium and water excretion through effects in the distal renal tubule. Combining the two produces additive blood pressure reduction and can reduce some potassium loss caused by hydrochlorothiazide.
The fixed-dose combination treats adults with hypertension after response to one or both individual components has been assessed. Current labeling states that the fixed-dose tablets are not indicated for initial therapy. Kidney function is assessed before and during treatment.
Patients whose blood pressure is not adequately controlled with lisinopril or hydrochlorothiazide alone can switch to 10 mg/12.5 mg or 20 mg/12.5 mg tablets. Further titration depends on blood pressure response. Hydrochlorothiazide increases are generally separated by two to three weeks, and the fixed-dose combination is not recommended with creatinine clearance at or below 30 mL per minute.
The combination carries a boxed warning for fetal toxicity. Other serious concerns include angioedema, severe low blood pressure, kidney dysfunction, high or low potassium, low sodium, acute angle-closure glaucoma, hypersensitivity, and rare blood-cell disorders. Concomitant neprilysin inhibitor use can raise angioedema risk.
The fixed-dose combination treats hypertension in adults.
No. Current labeling states that these fixed-dose tablets are not indicated for initial therapy.
Current strengths include 10 mg/12.5 mg, 20 mg/12.5 mg, and 20 mg/25 mg.
Yes. The boxed warning concerns fetal toxicity.
DailyMed - LISINOPRIL AND HYDROCHLOROTHIAZIDE tablet. https://www.dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9207c3bc-e12e-4017-8b85-0f928e744f64. Date Accessed October 1, 2026.
DailyMed - ZESTORETIC (lisinopril and hydrochlorothiazide) tablet. https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0d3a966f-f937-05a8-a90f-5aa52ebbd613. Date Accessed October 1, 2026.
Hydrochlorothiazide. StatPearls. https://www.ncbi.nlm.nih.gov/books/NBK430766/. Date Accessed October 1, 2026.
Lisinopril and Hydrochlorothiazide. MedlinePlus. https://medlineplus.gov/druginfo/meds/a601070.html. Date Accessed October 1, 2026.
Zestoretic. PubChem. https://pubchem.ncbi.nlm.nih.gov/compound/Zestoretic. Date Accessed October 1, 2026.